Sarcoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years old, male or female; 2. Patients diagnosed with sarcoma through histopathological examination at our hospital since 2020; 3. Patients with definitive molecular signatures, including inactivation of tumor suppressor genes, gene fusion/genomic rearrangement, and copy number variations confirmed by NGS or FISH; patients with suggestive molecular abnormalities (such as IHC demonstrating abnormal expression of relevant proteins); and patients exhibiting corresponding histopathological subtypes but lacking definitive molecular signatures. 4. Patients with adequate pre-treatment tissue specimens available for study (within 5 years; For needle biopsy specimens, about 20 slides or cutting rolls with a thickness of 5-10µm were used. For surgical specimens, about 10 slides or cutting rolls with a thickness of 5-10µm were used. The sections were placed on anti-detachment glass slides or the cutting rolls were placed in EP tubes. Be careful not to collect strong acid decalcified bone tissue samples. Pay attention to disinfect the microtome and the table, and replace different samples with new blades to prevent cross contamination.)
Exclusion criteria
Exclusion criteria: 1. Patients lacking detailed histopathological diagnostic reports and routine clinical follow-up data; 2. Patients with inadequate tissue samples for testing, or those who have only limited biopsy specimens; 3. Patients whose tissue samples fail to pass the quality control;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inactivation of tumor suppressor genes;Gene fusion or genomic rearrangement;Copy number variation; | — |
Countries
China
Contacts
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine